patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_767218 | REC_0010301 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 9.6 | 83 | male | 2 | 10 | 6 | 1 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:35:59.425882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324690 | REC_0010302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 7.9 | 63 | male | 1 | 13 | 5 | 4 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:59.426114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641204 | REC_0010303 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7 | 55 | male | 0 | 28 | 5.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 16.8 | true | MSS | 2026-03-15T05:35:59.426346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686573 | REC_0010304 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 9 | 54 | female | 0 | 15 | 5.3 | 6 | pembrolizumab 200 mg q3w | 7.3 | true | MSS | 2026-03-15T05:35:59.426579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192395 | REC_0010305 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 18 | 8.1 | 81 | female | 1 | 53 | 7 | 1 | pembrolizumab 200 mg q3w | 29 | false | MSS | 2026-03-15T05:35:59.426810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916774 | REC_0010306 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 14.9 | 82 | female | 1 | 27 | 5.9 | 6 | osimertinib 80 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:59.427042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815038 | REC_0010307 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 11.9 | 73 | female | 1 | 15 | 6.1 | 7 | osimertinib 80 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:59.427273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937016 | REC_0010308 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12 | 81 | male | 1 | 21 | 4.9 | 2 | osimertinib 80 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:59.427511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795965 | REC_0010309 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 10.1 | 74 | female | 1 | 11 | 5.7 | 3 | sotorasib 960 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:35:59.427742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432663 | REC_0010310 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.1 | 69 | female | 1 | 22 | 6.4 | 4 | sotorasib 960 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:59.428026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480997 | REC_0010311 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.8 | 72 | female | 1 | 14 | 5.1 | 4 | sotorasib 960 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:59.428404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424696 | REC_0010312 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.9 | 77 | male | 2 | 13 | 6.7 | 1 | alectinib 600 mg BID | 17.1 | true | MSS | 2026-03-15T05:35:59.428650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946895 | REC_0010313 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 6.6 | 74 | male | 0 | 15 | 6.5 | 1 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:59.428887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534134 | REC_0010314 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.5 | 64 | female | 1 | 3 | 4.6 | 9 | alectinib 600 mg BID | 16.7 | true | MSI-H | 2026-03-15T05:35:59.429123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812357 | REC_0010315 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.3 | 80 | female | 1 | 18 | 5.7 | 5 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:35:59.429363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615900 | REC_0010316 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.6 | 72 | female | 1 | 64 | 5.7 | 10 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:59.429591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128905 | REC_0010317 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.9 | 54 | male | 0 | 2 | 4.8 | 6 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:59.429823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618601 | REC_0010318 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.8 | 61 | female | 1 | 6 | 4.2 | 6 | entrectinib 600 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:35:59.430057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929835 | REC_0010319 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.2 | 68 | male | 0 | 64 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:35:59.430293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957867 | REC_0010320 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.5 | 68 | female | 0 | 18 | 5.7 | 5 | osimertinib 80 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:35:59.430524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998807 | REC_0010321 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 8.4 | 70 | female | 1 | 10 | 3.4 | 6 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:35:59.430757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351690 | REC_0010322 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 2.2 | 73 | female | 2 | 0 | 6.2 | 1 | osimertinib 80 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:59.430981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333967 | REC_0010323 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.7 | 59 | male | 0 | 64 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.1 | false | MSS | 2026-03-15T05:35:59.431262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571350 | REC_0010324 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.1 | 63 | male | 0 | 13 | 6.1 | 6 | osimertinib 80 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:59.431502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392847 | REC_0010325 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 10.4 | 63 | female | 1 | 17 | 5.8 | 4 | alectinib 600 mg BID | 15 | true | MSS | 2026-03-15T05:35:59.431738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724968 | REC_0010326 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.3 | 77 | female | 2 | 70 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 26 | true | MSS | 2026-03-15T05:35:59.431968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427303 | REC_0010327 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 13.9 | 68 | female | 0 | 13 | 5.1 | 9 | alectinib 600 mg BID | 11.6 | true | MSI-H | 2026-03-15T05:35:59.432233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842170 | REC_0010328 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 26 | 4.9 | 66 | female | 0 | 15 | 7.7 | 0 | pembrolizumab 200 mg q3w | 41.1 | true | MSS | 2026-03-15T05:35:59.432473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919959 | REC_0010329 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.2 | 80 | female | 1 | 57 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:59.432708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562620 | REC_0010330 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 3.8 | 66 | female | 1 | 8 | 5.1 | 1 | sotorasib 960 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:59.432935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326506 | REC_0010331 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.7 | 74 | female | 1 | 68 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:59.433163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464215 | REC_0010332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.8 | 67 | female | 0 | 15 | 6.2 | 6 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.433396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133985 | REC_0010333 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 7.4 | 53 | male | 0 | 12 | 6.4 | 2 | entrectinib 600 mg daily | 21 | true | MSS | 2026-03-15T05:35:59.433626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264740 | REC_0010334 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8 | 60 | female | 1 | 21 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:35:59.433854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512271 | REC_0010335 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.8 | 68 | female | 1 | 20 | 5.1 | 3 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:59.434084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838011 | REC_0010336 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 14.6 | 72 | male | 0 | 4 | 5.7 | 3 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:35:59.434380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252677 | REC_0010337 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 5.2 | 73 | female | 1 | 11 | 7.2 | 2 | alectinib 600 mg BID | 24.2 | false | MSS | 2026-03-15T05:35:59.434611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109385 | REC_0010338 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 10.4 | 50 | female | 0 | 12 | 7.4 | 4 | entrectinib 600 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:35:59.434843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417196 | REC_0010339 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.6 | 68 | female | 1 | 16 | 6.9 | 4 | sotorasib 960 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:59.435074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349215 | REC_0010340 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.8 | 68 | male | 1 | 56 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.8 | true | MSS | 2026-03-15T05:35:59.435305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915103 | REC_0010341 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.3 | 66 | female | 0 | 9 | 5.2 | 6 | alectinib 600 mg BID | 8 | true | MSS | 2026-03-15T05:35:59.435538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378480 | REC_0010342 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.2 | 61 | male | 1 | 15 | 7.1 | 1 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:35:59.435772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118088 | REC_0010343 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 14 | 68 | female | 0 | 6 | 4.5 | 1 | alectinib 600 mg BID | 17.3 | false | MSI-H | 2026-03-15T05:35:59.436005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413418 | REC_0010344 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 13.9 | 68 | female | 1 | 19 | 5.7 | 2 | osimertinib 80 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:59.436273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628123 | REC_0010345 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.3 | 69 | female | 1 | 21 | 4.4 | 6 | osimertinib 80 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:35:59.436510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777144 | REC_0010346 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 47 | male | 0 | 15 | 7.7 | 7 | sotorasib 960 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:35:59.436746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733917 | REC_0010347 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.7 | 58 | male | 0 | 15 | 5 | 8 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:35:59.436979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542290 | REC_0010348 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 7.2 | 57 | female | 0 | 12 | 4.9 | 1 | sotorasib 960 mg daily | 23 | true | MSS | 2026-03-15T05:35:59.437209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833650 | REC_0010349 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.8 | 61 | female | 1 | 20 | 5.8 | 1 | sotorasib 960 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:59.437500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623254 | REC_0010350 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9.8 | 63 | male | 1 | 14 | 4.3 | 2 | osimertinib 80 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:59.437737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773188 | REC_0010351 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.6 | 58 | male | 0 | 36 | 6.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:59.437971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659489 | REC_0010352 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11.7 | 77 | female | 0 | 17 | 7.4 | 6 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:59.438202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322550 | REC_0010353 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.9 | 72 | female | 1 | 2 | 5.4 | 1 | entrectinib 600 mg daily | 23 | true | MSS | 2026-03-15T05:35:59.438433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465479 | REC_0010354 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 4.8 | 75 | female | 1 | 8 | 5.8 | 2 | entrectinib 600 mg daily | 22.6 | false | MSS | 2026-03-15T05:35:59.438662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429000 | REC_0010355 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 7.9 | 70 | female | 2 | 12 | 5.7 | 5 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:35:59.438905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786560 | REC_0010356 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 9.1 | 81 | female | 2 | 6 | 5.6 | 5 | osimertinib 80 mg daily | 8.7 | true | MSS | 2026-03-15T05:35:59.439148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284490 | REC_0010357 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.5 | 76 | female | 1 | 6 | 5.3 | 4 | entrectinib 600 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.439387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485082 | REC_0010358 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 20.4 | 65 | female | 0 | 12 | 7 | 1 | osimertinib 80 mg daily | 34.1 | false | MSS | 2026-03-15T05:35:59.439625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784337 | REC_0010359 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.5 | 61 | male | 0 | 13 | 7.1 | 8 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:35:59.439862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393188 | REC_0010360 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.1 | 48 | female | 0 | 27 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.2 | false | MSS | 2026-03-15T05:35:59.440155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208602 | REC_0010361 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 7.3 | 56 | male | 0 | 31 | 5.3 | 6 | sotorasib 960 mg daily | 4.3 | true | MSS | 2026-03-15T05:35:59.440406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753774 | REC_0010362 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 8.6 | 71 | female | 2 | 23 | 4.9 | 2 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:59.440732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858702 | REC_0010363 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 20.2 | 62 | female | 1 | 18 | 5.6 | 3 | pembrolizumab 200 mg q3w | 12.5 | false | MSI-H | 2026-03-15T05:35:59.440993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969375 | REC_0010364 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.5 | 71 | female | 2 | 12 | 3.1 | 6 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:59.441250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921149 | REC_0010365 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 16.1 | 66 | female | 0 | 19 | 4.1 | 2 | osimertinib 80 mg daily | 28 | true | MSI-H | 2026-03-15T05:35:59.441497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557830 | REC_0010366 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.6 | 73 | female | 1 | 25 | 6.8 | 1 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:59.441732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781727 | REC_0010367 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.6 | 71 | female | 1 | 10 | 6.5 | 4 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:59.441969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897651 | REC_0010368 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.8 | 70 | female | 2 | 12 | 4.9 | 7 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:59.442198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810416 | REC_0010369 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 17.5 | 61 | male | 0 | 14 | 5 | 0 | osimertinib 80 mg daily | 34.2 | false | MSS | 2026-03-15T05:35:59.442436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963965 | REC_0010370 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 18.3 | 71 | female | 2 | 24 | 6.3 | 3 | osimertinib 80 mg daily | 19 | false | MSS | 2026-03-15T05:35:59.442669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961953 | REC_0010371 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 19.9 | 70 | female | 2 | 21 | 4.7 | 2 | alectinib 600 mg BID | 10.4 | true | MSI-H | 2026-03-15T05:35:59.442909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108013 | REC_0010372 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 14.7 | 83 | male | 1 | 19 | 5.5 | 6 | entrectinib 600 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:59.443148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740975 | REC_0010373 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 21.9 | 74 | female | 1 | 11 | 7.7 | 6 | entrectinib 600 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:59.443381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322641 | REC_0010374 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.4 | 66 | female | 0 | 6 | 6.5 | 7 | entrectinib 600 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:59.443617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395712 | REC_0010375 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 18.6 | 73 | female | 1 | 19 | 5.2 | 8 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:59.443947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525203 | REC_0010376 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.5 | 72 | female | 2 | 19 | 6.2 | 5 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:59.444226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141160 | REC_0010377 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 7.8 | 72 | female | 2 | 19 | 5.7 | 6 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:59.444482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858058 | REC_0010378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 5.4 | 66 | female | 0 | 13 | 5 | 2 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:35:59.444721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939944 | REC_0010379 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.9 | 58 | male | 1 | 40 | 5.8 | 7 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:35:59.444955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929959 | REC_0010380 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 12 | 13.6 | 60 | female | 0 | 23 | 4.6 | 1 | sotorasib 960 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:59.445196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881332 | REC_0010381 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15.5 | 75 | female | 0 | 16 | 3.9 | 4 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:59.445432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234442 | REC_0010382 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.5 | 67 | female | 1 | 6 | 5.2 | 2 | sotorasib 960 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:59.445673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598693 | REC_0010383 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.2 | 55 | male | 1 | 13 | 4.1 | 8 | osimertinib 80 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:59.445941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965007 | REC_0010384 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12 | 75 | female | 0 | 17 | 5 | 2 | sotorasib 960 mg daily | 20.9 | true | MSI-H | 2026-03-15T05:35:59.446199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477198 | REC_0010385 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 11.6 | 74 | female | 2 | 18 | 5.2 | 8 | alectinib 600 mg BID | 4.1 | false | MSI-H | 2026-03-15T05:35:59.446447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246476 | REC_0010386 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 11.9 | 59 | male | 0 | 12 | 5.5 | 6 | osimertinib 80 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:59.446687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735695 | REC_0010387 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 16.1 | 80 | female | 3 | 9 | 6 | 2 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.446935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353975 | REC_0010388 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15.3 | 61 | female | 1 | 9 | 5.2 | 5 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:59.447282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862838 | REC_0010389 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9 | 64 | female | 1 | 9 | 5.9 | 5 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:59.447526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812458 | REC_0010390 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 17.4 | 71 | male | 1 | 22 | 4.7 | 1 | osimertinib 80 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:59.447766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227779 | REC_0010391 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.8 | 67 | female | 0 | 20 | 3.5 | 1 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.448005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610834 | REC_0010392 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.4 | 82 | female | 1 | 16 | 6.3 | 2 | pembrolizumab 200 mg q3w | 17.5 | true | MSS | 2026-03-15T05:35:59.448405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768489 | REC_0010393 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.3 | 69 | female | 1 | 67 | 7.8 | 2 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:59.448665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401598 | REC_0010394 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.9 | 54 | female | 0 | 38 | 7.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.4 | false | MSS | 2026-03-15T05:35:59.448907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884058 | REC_0010395 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8 | 69 | female | 1 | 15 | 3.8 | 6 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:59.449143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855386 | REC_0010396 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.2 | 54 | female | 0 | 12 | 6.3 | 1 | osimertinib 80 mg daily | 5.4 | true | MSI-H | 2026-03-15T05:35:59.449381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556123 | REC_0010397 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 13.8 | 79 | female | 1 | 4 | 2.9 | 1 | sotorasib 960 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:59.449622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845325 | REC_0010398 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 7.2 | 59 | female | 0 | 20 | 4.4 | 1 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.449860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530210 | REC_0010399 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 17.4 | 65 | female | 1 | 17 | 5.9 | 7 | osimertinib 80 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:35:59.450101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885848 | REC_0010400 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8.8 | 74 | female | 1 | 16 | 5.2 | 4 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:59.450333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.